Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,088 total articles
Kimbell Royalty Partners (KRP) trades like an income-first royalty vehicle: high quarterly distributions, minimal upkeep CapEx and steady cash flow tied to production and commodity cycles. Valuation metrics show a mixed picture - attractive EV/EBITDA but stretched on free cash flow coverage - creating an entry window for investors who want yield pl…
Red Cat is morphing from a niche drone supplier into a drone-as-a-service rollup after the Apium acquisition and a strategic partnership with Ukraine's Spetstechnoexport. Revenue is accelerating (FY2025 $40.7M, +161% YoY; Q4 revenue $26.24M beat), but the market already prices aggressive expansion: market cap ~$1.52B and an EV/sales multiple north …
Apple is a buy here on a tactical basis. A CEO transition that markets treated as uncertain is now priced in, technical momentum is constructive, and the company’s cash-generation gives management optionality for buybacks and product bets. Entry at $268, stop at $255, target $305 over a mid-term (45 trading days) horizon. Risk remains—valuation, ge…
Micron's recent run has been powered by a dramatic recovery in DRAM pricing, an acute supply-side squeeze (helium shortages and capex dynamics), and visible buy-side momentum. Valuation on trailing metrics is elevated versus a long-term trough but still reasonable relative to near-term cash generation: market cap ~$507B, P/E ~21, EV/EBITDA ~14.5, a…
Pampa Energía (PAM) looks like a pragmatic trade rather than a long-term thematic buy right now. At $83.06 the stock sits near technical support around the 50-day average, trades at a modest PE of 11.2 and PB of 1.24, and shows heavy short-volume activity. There are no imminent company-specific catalysts, but a disciplined buy with a defined stop a…
Coherent stands to benefit from a renewed datacenter optics buildout driven by hyperscaler capex. The stock has momentum, institutional backing and low days-to-cover on short interest — but carries elevated multiples and negative free cash flow. Entry at $350, stop $315, target $440 for a position trade over the next 46–180 trading days.
TAT Technologies (TATT) has been punished more for headline noise than fundamentals. Strong Q2 2025 results, a market cap under $500M and an aftermarket business with durable demand make this a compelling, risk-defined long. Enter near current levels, stop under $30, target a recovery toward the $46-$50 range over the mid term.
<p>Groupe Dynamite, the Canadian fast-fashion operator behind Dynamite and Garage, looks positioned for a re-rate as mall traffic normalizes and digital gains compound earnings. This trade idea buys a tactical entry around $3.00 with a conservative stop at $2.10 and a first target at $6.00, capturing upside from margin recovery, inventory normaliza…
Aegon Ltd. looks set for a re-rating while trading near the top of its 52-week range. The company combines a meaningful U.S. footprint with active capital management, a 4.65% yield, and a conservative valuation (P/E ~11.4, P/B ~1.38). This trade targets a mid-term rerating into $10 with a clear entry at $8.03 and a stop at $7.20.
Compass Minerals looks set to continue its recovery run. The stock is trading near $25.56, supported by bullish technicals and a meaningful free cash flow stream that cushions a leveraged balance sheet. This trade idea targets a move to the 52-week high at $27 and provides a plan for traders who want to play both near-term weather-driven upside and…
CZMWF looks like it's forming a low-volatility base around the low $30s with bullish momentum indicators and abnormally high short interest. This is a tactical long trade on the view that price action, a thin float, and positive technicals can produce a 15-20% move within a mid-term window. The trade is higher-risk because the stock trades OTC with…
Imperial Oil (IMO) looks set to compound shareholder returns as upstream volumes rise and free cash flow remains robust. With production guidance for 2026, a healthy dividend, and a conservative debt profile, the risk-reward now favors a long exposure. Technicals and elevated short interest argue for disciplined sizing and a defined stop.
Workday is trading well below last years highs but still generates strong free cash flow and carries a defensible position in HR/Finance cloud software. This trade targets a re-rating to a mid-teens EV/FCF multiple as enterprise budgets stabilize and AI-driven integrations accelerate adoption. Entry $130.00, target $160.00, stop $115.00 - long ter…
Molina Healthcare's stock has been knocked down by a volatile earnings quarter and Medicaid margin pressure, but the underlying business, predictable revenue streams, and an attractive valuation make it a compelling long-term trade. This note lays out a clear entry, stop and target, the fundamental case, catalysts to watch, and the risks that could…
Gold Fields (GFI) looks positioned to re-rate as Salares Norte transitions from optionality to real production potential. At $46.50 the stock offers a mix of yield (2.46%), a sub-13x P/E, and bullish technical momentum. This trade idea outlines an entry at $46.50, a stop at $43.00 and a target at $58.00 over a mid-term horizon (45 trading days).
O'Reilly traded to a 52-week low after a narrow Q4 miss and margin pressure, but fundamentals and technicals argue this pullback is a buying window. We lay out an explicit entry at $93.82, a stop at $86.77 and a $110 target over the next 180 trading days.
CZMWF sits at the crossroads of solid technical momentum and poor market optics: trading on OTC Link with low liquidity, extreme short interest, and noisy daily volumes. Technical indicators show bullish momentum around the $32 area, and intermittent short-volume spikes create the potential for a squeeze. This is a high-risk, actionable long setup …
POET (ticker: POET) is a tiny photonics platform with a $1.57B market cap trading on headlines about PFIC remediation, strategic partnerships, and sample timelines for AI optical modules. The stock is volatile and crowded — we outline a position trade (120 trading days) with clear entry, stop and ambitious upside while flagging the structural execu…
IREN is a differentiated infrastructure play: vertically integrated, renewable-rich campus sites and a $9.7B hyperscaler engagement put the company at the center of AI compute bottlenecks. The stock has rallied but still trades on stretched multiples and a capital-hungry expansion plan that market reports peg near $6B of new funding. This trade ide…
Amneal's move into metered-dose inhalation products, a progressing biosimilar program, and improving free cash flow create a favorable risk/reward from current levels. We recommend a tactical long with a mid-term horizon to capture commercial ramp and clinical readouts while respecting operational and regulatory risks.
Columbia Seligman Premium Technology Growth Fund (STK) is a tech-focused covered-call closed-end fund that currently yields ~4.0%, trades at a low earnings multiple, and shows strong technical momentum. For investors who want tech exposure with income and a measure of downside cushioning, STK offers a more balanced path than a straight growth bet o…
Oracle has moved from an AI underdog to a central infrastructure supplier as OpenAI and Anthropic chase scale. With partner-funded data-center expansion, accelerating RPO and a string of recent commercial wins, Oracle is positioned to capture the revenue and margin upside from the enterprise AI arms race. This trade targets continued re-rating over…
Applied Optoelectronics (AAOI) has moved from speculative turnaround to commercial momentum: multiple hyperscale volume orders for 800G and 1.6T transceivers, a major new Texas manufacturing campus and plans to scale to 500k combined units/month underpin a long-term trade. The valuation is rich and fundamentals show losses and negative free cash fl…
Cybin (CYBN) is a clinical-stage neuropsychiatric company trading at a modest ~$298M market cap. Recent regulatory and policy signals, expanding analyst coverage, and a live Phase II program create an asymmetric risk/reward for a tactical long. We upgrade to a buy and lay out a clear entry at $8.00, a stop at $5.50 and targets at $12.00 (mid) and $…
Travere (TVTX) looks attractively positioned if FILSPARI (sparsentan) captures FSGS market share or becomes an acquisition target. The stock trades at a market cap of roughly $3.58B despite negative earnings, modest free cash flow, and material leverage. This trade idea lays out a clear entry, stop and target with a long-term horizon while flagging…
